Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.

Abstract: Disclosed herein are method for producing hydridoma cell lines producing monoclonal human natural IgM antibodies and hybridoma cells produced by the methods. The antibodies are the monoclonal equivalents of circulating human natural antibodies.

Abstract: A method for reducing gastrointestinal inflammation in an animal is disclosed. The method involves administering to the animal an agent that reduces the bioavailability in the animal of a prostaglandin or leukotriene lipid precursor wherein the agent comprises an antibody.

Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.

Abstract: An immunoassay for the determination of myocardial necroses using antibodies to troponin T and a binding partner B for troponin T or for the an antibody, whereby either the antibody or the binding partner B is labelled with a determinable group. The immunological complex formed which contains the determinable group is isolated by separation of the phases and the determinable group is determined in one of the phases. Furthermore, monoclonal and polyclonal antibodies to troponin T are described with a cross-reactivity of less than 5% to skeletal muscle troponin T and less than 2% to troponin I and other myofibrillar proteins.

Abstract: The present invention provides a monoclonal antibody useful for immunoassay of human serum amyoloid A (SAA), which can be used as a marker for inflammations based on the agglutination reaction, as well as a reagent for immunoassay comprising the monoclonal antibody, and a method for immunoassay utilizing the monoclonal antibody. In a preferred embodiment, the monoclonal antibody recognizes at least one epitope of human amyloid A and it agglutinates with human serum amyloid A. The present invention improves the specificity of immunoassay by utilizing the agglutination reaction of SAA and monoclonal antibody in the presence or absence of other monoclonal antibodies recognizing SAA.

Abstract: Methods for treating diabetes by administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta (TGF-&bgr;) superfamily of structurally-related growth factors (e.g., GDF-11) are disclosed. Also disclosed are methods for upregulating expression of hexose transporters, such as GLUT4 and GLUT1, in a subject by administering an inhibitor of GDF-8. Also disclosed are methods for increasing glucose uptake by cells in a subject, by administering an inhibitor of GDF-8.

Abstract: Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from systemic lupus erythematosus (SLE). In the case of the peptides it is preferably a question of the C terminus of H1 with the sequence section 187-211 and the N termini of H2B with the sequence sections 1-35 and 36-76, which are capable of cross reactions with the autoantibodies (anti-histone-antibodies). The invention furthermore provides ways of forming monoclonal antibodies and antiidiotypical antibodies, which are directed against autoantibodies. The diagnosis of SLE is possible in accordance with the invention with a high degree of certainty and the monoclonal antibodies directed against the autoantibodies are suitable for the production of medicaments for the therapy of SLE.

Abstract: Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof are used in pharmaceutical preparations and in diagnosis. Cells which express these antibodies, antibody fragments, mixtures or derivatives thereof are also disclosed.

Abstract: Isolated proteins comprising the T-cell surface antigen CD97 &agr; are provided. Compositions and methods for making and detecting CD97 &agr; are also provided. Further, the invention provides diagnostic and therapeutic methods and compositions for medical conditions involving CD97.

Abstract: The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.

Abstract: Disclosed is human haemopoietic maturation factor polypeptides and DNA (RNA) encoding such haemopoietic maturation factor polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and the use of such polypeptides for treating leukemia, auto-immune diseases and blood related disorders. Antagonists against such polypeptides and their use as a therapeutic to prevent expansion of T-cell populations is also disclosed. Diagnostic assays are also disclosed which detect the presence of mutations in the haemopoietic maturation factor nucleic acid sequences and altered levels of the protein.

Abstract: Proteins comprising one or more copies of von Willebrand factor type A domain play important roles in host defense mechanisms, such as immune response, inflammation, and hemostasis. Zvwf1 is a new member of this superfamily.

Abstract: Peptides derived from prostate specific antigen (PSA) that correspond to the immunodominant epitopes found in the native antigen are disclosed. These peptides were identified using a method that predicts continuous, immunodominant epitopes. Anti-PSA antibodies, methods for their production and their use in diagnostic assays also are disclosed.

Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of C-terminal hGPIIb fragment of the platelet receptor GPIIb-IIIa in a body fluid sample are disclosed.

Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.

Abstract: The present invention provides a novel complex of hK2 and PI-6 and methods of using the novel complex. The novel complexes of hK2 and PI-6 of the present invention exist at an elevated level in prostate cancer tissues. Therefore, the hK2-PI6 complexes of the present invention may be used as a serum marker for detecting prostate cancer. They may also be used as an immunohistological marker to detect prostate cancer tissues. In accordance with the present invention, the hK2-PI6 complexes of the present invention may be detected in patient tissue samples by immunohistochemical and/or in patient fluid samples by in vitro immunoassay procedures. Diagnostic kits and diagnostic methods for detecting the existence of prostate cancer are also provided.

Abstract: Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies and methods of use are provided.

Abstract: The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.

Abstract: Methods are disclosed for the identification of key diagnostic antibodies and antigens characteristic of a disease state of interest. Key diagnostic antibodies and antigens, diagnostic kits, and methods for diagnosis, are disclosed for Alzheimer's disease.

Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.

Abstract: The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to &agr;2-antiplasmin crosslinked to fibrin (&agr;2AP-FX) which does not inhibit plasma &agr;2-antiplasmin (&agr;2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward &agr;2-antiplasmin crosslinked to fibrin which does not inhibit plasma &agr;2AP together with a thrombolytic agent.

Abstract: The present invention is directed to antibodies and antibody fragments that bind specifically to the active conformation of human von Willebrand factor. Most preferred are recombinantly produced single chain variable immunoglobulin fragments. Because the antibodies or antibody fragments act only at the sites of thrombus formation and do not interfere with the normal activity of circulating platelets, they are particularly well suited for use as antithrombotic agents in a wide variety of applications.

Abstract: A method of assaying the growth hormone status of an individual by immuno-assay for the 150 KDa Insulin-like Growth Factor ternary complex (IGF/IGFBP-3/ALS). Alternatively, a binary complex may be assayed. The method involves capturing the IGFBP complex with a first antibody coupled to a solid phase and detecting the complex with a second antibody coupled to a label. A set of monoclonal and polyclonal antibodies usefutl for the assay is also provided.

Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.

Abstract: Coagulation protein antagonists are disclosed, which include monoclonal-type antibodies and related cell lines disclosed for the production of specific, neutralizing antibodies against factors VII and VIIa and the tissue factor/factor VIIa bimolecular complex, which antibodies are useful for the prevention or treatment of thrombotic and related diseases, for immunoaffinity isolation and purification of factors VII and VIIa and the tissue factor/factor VIIa complex, and for determination of factors VII or VIIa and the tissue factor/factors VII or VIIa complex in a biological sample.

Abstract: The present invention provides an antibody which specifically reacts with an epitope of a polypeptide comprising the amino acid sequence X-Y-CYS GLN GLU GLU GLU CYS PRO ASP PRO TYR LEU CYS SER PRO VAL THR ASN ARG CYS GLU CYS THR PRO VAL LEU CYS ARG MET TYR CYS LYS PHE TRP ALA LYS ASP GLU LYS GLY CYS GLU ILE CYS LYS CYS GLU GLU LEU CYS GLN ASN GLN ASN CYS THR LYS ASP MET LEU CYS SER SER VAL THR ASN ARG CYS ASP CYS GLN ASP PHE LYS CYS PRO GLN SER TYR CYS-Z (SEQ. ID NO. 1) wherein X is MET or absent; Y is 0-28 amino acids of the sequence LYS MET CYS TRP ASN LYS GLY CYS PRO CYS GLY GLN ARG CYS ASN LEU HIS ARG ASN GLU CYS GLU VAL ILE ALA GLU ASN ILE GLU, (SEQ. ID NO. 2) with the proviso that if part of the sequence is present, it is a carboxy-terminal part of the sequence including the carboxy-terminal GLU and wherein Val may be preceded by Gly; and Z is absent or all or a part of the sequence Pro110-Lys156 shown in FIG. 7 (SEQ. ID NO.

Abstract: Measurements of elevated levels of riboflavin carrier protein (RCP) can be used to detect breast, liver, ovarian, and endometrial cancers. Stains for riboflavin carrier protein can be used to visualize malignancies in tissue specimens. The new technique is particularly well-suited for the early detection of breast cancer. With a radioimmunoassay for RCP, we have observed that serum RCP levels were significantly elevated in women with breast cancer as compared to control subjects. A serum RCP level ≧1.0 ng/ml was highly predictive of the presence of breast cancer (other than in pregnant females).

Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.

Abstract: The present invention is drawn to a method for the quantitative determination of human acute phase serum amyloid A protein (A-SAA) comprising contacting a sample of a biological fluid with antibody specific for A-SAA, the sample being reacted with an organic solvent prior to or simultaneous with antibody contact. The organic solvent is suitably a C1 or C4 alcohol and the antibody can be used on the solid phase and as a component of the detection system of an enzyme linked immunosorbant assay. The method provides a sensitive and reliable measure of A-SAA and inflammatory status which can be used for the diagnosis and clinical management of both acute and chronic inflammatory conditions.

Abstract: The invention deals with the use of a reactive compound in immunological analyses. The compound is ouabain or its analog to which another compound, labeled by radioiodine or by a fluorogen, is coupled. The invention covers also the method to measure ouabain or its analog in plasma to diagnose cardiovascular and endocrine diseases and other harmful conditions.

Abstract: This invention concerns PAPP-A, its immunodetection and the clinical benefits of such immunodetection. Specifically, the invention includes monoclonal antibodies against PAPP-A and the use of these antibodies to detect PAPP-A at a very early stage of pregnancy. The invention also covers the use of the monoclonal antibodies for the detection of specific types of cancer and Down's Syndrome pregnancies.

Abstract: The present invention relates to a method of determining, on a test sample, the occupation of the cellular GPIIb/IIIa receptor by an antagonist of fibrinogen, characterized in that the number of receptors occupied is determined in the said sample with the aid of an antibody MAb1 which is a competitor for the antagonist, and the total number of occupied or unoccupied receptors is determined with the aid of a so-called noncompetitor antibody MAb2 specific for the occupied or unoccupied receptor and the rate of occupation of the GPIIb/IIIa receptors in the sample is deduced therefrom.

Abstract: The present invention concerns a method of treating bacteremia, sepsis and other forms of toxemia caused by Gram-positive bacteria and mycobacteria comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.